ArticleActa dermato-venereologica2026
From Onset to Outcome: A Long-term Retrospective, Single centre Study of Guttate Psoriasis from Israel.
Article in Acta dermato-venereologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Guttate psoriasis is often precipitated by strepto-coccal infections and is generally regarded as a mild subtype of psoriasis; however, its potential associations with systemic comorbidities are insufficiently explored. In this study, we aimed to evaluate the association of guttate psoriasis with systemic comorbidities such as metabolic syndrome and psoriatic arthritis and identify factors affecting recurrence. In this retrospective single-centercentre study, we reviewed the data of patients with the first eruption of guttate psoriasis between 1998 and 2020 and at least 4 years of follow-up data. Demographic information and medical data (type of treatment, psoriasis flare-ups, remission of disease, and development of metabolic syndrome and/or psoriatic arthritis) were retrieved. Of 395 patients included (mean follow up, 83±34.7 months), 34.9 % experienced at least one recurrence, 14.68 % had multiple recurrences, 5.6 % developed psoriatic arthritis, and 8.6 % had metabolic syndrome. Male sex, topical treatment and residual disease were significant risk factors for recurrence. Psoriatic arthritis was strongly associated with multiple recurrences, while a possible association with metabolic syndrome was observed, highlighting the importance of careful long-term monitoring in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.